Detectable MRD after induction therapy in B-ALL is commonly associated with cytogenetic aberrations linked to poor outcomes, such as BCR::ABL1 and KMT2A rearrangements [2]. The gene discussed is BCR; the disease is acute lymphoblastic leukemia.